Brief: Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726

MetaVia

15/04/2025 12:23

April 15 (Reuters) - MetaVia Inc MTVA.O:

METAVIA ANNOUNCES POSITIVE TOP-LINE DATA FROM THE 4-WEEK PHASE 1 MAD TRIAL OF DA-1726, A NOVEL 3:1 RATIO GLP-1 GLUCAGON DUAL RECEPTOR AGONIST TO TREAT OBESITY, SHOWING COMPELLING WEIGHT LOSS AND SAFETY EFFECTS WITH POTENTIAL BEST-IN-CLASS GLUCOSE CONTROL (GLP-1R), WAIST REDUCTION (GCGR), AND TOLERABILITY

METAVIA INC: ADDITIONAL COHORTS BEING ADDED TO DETERMINE MAXIMUM TOLERATED DOSE

METAVIA INC: STUDY SHOWS STRONG SIGNAL OF GLUCAGON EFFICACY AT DAY 33 AT 32 MG DOS

METAVIA: WITH NO TITRATION, DEMONSTRATED MAXIMUM WEIGHT LOSS OF 6.3% AND MEAN WEIGHT LOSS OF 4.3% AT DAY 26 AT 32 MG DOSE

METAVIA: PHASE 1 PART 3 TO INCLUDE WEGOVY EARLY DROP-OUT PATIENTS TO EXPLORE POTENTIAL SUPERIORITY OF DA-1726 ON SAFETY AND TOLERABILITY

Source text: ID:nPn4NKW7va

Further company coverage: MTVA.O

 ((Reuters.Briefs@thomsonreuters.com;))